A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks
- Gathe, J.
- Da Silva, B.A.
- Cohen, D.E.
- Loutfy, M.R.
- Podzamczer, D.
- Rubio, R.
- Gibbs, S.
- Marsh, T.
- Naylor, C.
- Fredrick, L.
- Bernstein, B.
ISSN: 1525-4135
Argitalpen urtea: 2009
Alea: 50
Zenbakia: 5
Orrialdeak: 474-481
Mota: Artikulua